期刊论文详细信息
| Journal of Translational Medicine | |
| Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) | |
| Keynote Speaker Presentation | |
| 关键词: Metastatic Melanoma; Ipilimumab; Vemurafenib; BRAF Inhibitor; Maculopapular Rash; | |
| DOI : 10.1186/1479-5876-13-S1-K8 | |
| 来源: Springer | |
 PDF
|
|
【 摘 要 】
【 授权许可】
CC BY
© Puzanov; licensee BioMed Central Ltd. 2015
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311107308847ZK.pdf | 237KB |  download |
878987797
028-85220240
